Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
about
Gemcitabine and platinum combinations in pancreatic cancer.Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancerEvolution of systemic therapy for advanced pancreatic cancer.MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 functionPancreatic cancer: the evolving role of systemic therapy.Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Developments in the systemic therapy of pancreatic cancer.Randomized phase II trials: a long-term investment with promising returnsAdvanced pancreatic cancer: is there a role for combination therapy?Review article: chemotherapy for pancreatic cancer.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersGemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer modelRadiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.Gemcitabine in the treatment of metastatic pancreatic cancer.The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.A comparison of phase II study strategies.CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling.Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
P2860
Q33344048-90792E22-BB48-4412-AC2E-37C14DD27E7BQ33389637-CBEE7B43-94AF-4C62-837D-68C49D52C633Q33409519-CDF8D15C-919C-433E-AFBA-F9EC96A6366AQ33428016-7C567D09-CDA8-4937-B748-0C0C37B8FC7CQ33557413-DEAB9091-89F9-45ED-9697-C14C003F7FEBQ33930068-34CE99DD-8DDD-4223-AAFD-7A63B86ED10FQ34515547-06BD8AC2-7D9D-4E6A-B7E0-B2582A46055FQ34665177-443A01F3-4A1D-4D0A-B1F5-6BC4C7FFF571Q34810745-C867C9E3-E94F-42ED-9648-EAA95BF3A1BAQ34818494-428842B8-9619-4650-80BF-957E00C9B63AQ35087326-C28DE5AE-BCAA-42DC-87C2-368BBE74E414Q35115259-05786500-435E-4180-9CAF-31833C7D3197Q35576200-3DCE9EA0-A526-4839-A400-DAF535B16144Q35599597-5D8A4BD3-DEA7-4155-9635-174A51646108Q35776091-3B633C87-7CEA-4760-A7F2-2ED244093B7FQ36384541-67AE779F-02C9-4D5B-BAA4-3746494FDB40Q36476666-A222AB9C-9F10-4A62-87C0-9EAAE8EE6546Q36831339-FD4CB6CE-4AA3-48A9-A6D5-5343EC0B09ABQ36831348-478BEA61-8526-4A5E-9ECF-A96B2B0CBEA9Q37134412-D8A50074-2451-4B05-8398-DEA9B39757ADQ37235527-3039553A-C29F-47A8-BD06-7DD61618CF49Q37375886-CB68D8F1-9251-4294-8ACC-E671E4F3A10BQ37398718-4D968772-D878-42F2-8712-C3016C76FB7EQ39016327-EB060DE2-C6D4-4EED-970A-47D461BC2AFAQ39022032-B9ACF720-C811-4AD0-87F4-F4123FC066E4Q39466674-67F6FCBD-CE2D-4BB1-9862-C36C45FE82ABQ44906700-D6320C19-F9B5-44B5-83F2-9D963C96C7B3Q46845221-75304C3A-87EA-4D1E-9F36-243C552387B3
P2860
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@ast
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@en
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@nl
type
label
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@ast
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@en
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@nl
prefLabel
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@ast
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@en
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@nl
P2093
P2860
P1433
P1476
Phase II study of gemcitabine ...... advanced pancreatic carcinoma.
@en
P2093
A F Shields
L K Heilbrun
M M Zalupski
P A Philip
P Arlauskas
V K Vaitkevicius
P2860
P304
P356
10.1002/1097-0142(20010801)92:3<569::AID-CNCR1356>3.0.CO;2-D
P407
P577
2001-08-01T00:00:00Z